Back to Previous Page

PCSK9 (human) AlphaLISA Detection Kit, 500 Assay Points

ITEM#: 2013-AL270C

MFR#: AL270C

The AlphaLISA® Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Detection Kit is designed for detection and quantitation of human PCSK9 in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation ste

GSA_Logo ECAT_Logo
The AlphaLISA® Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Detection Kit is designed for detection and quantitation of human PCSK9 in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay. One antibody targets the pro-domain of PCSK9..Formats: Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Features: No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia. AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.